Abstract
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecular chaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60, the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotective but a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examples of specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicate a pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response to treatment, as well as for preventing and treating CVD.
Keywords: Chaperonin, heat shock protein 60, cardiomyocytes, heart failure, cardiovascular disease, atherosclerosis, apoptosis, microRNAs (miRs), diabetes, Atrial fibrillation
Current Pharmaceutical Design
Title: Heat Shock Protein-60 and Risk for Cardiovascular Disease
Volume: 17 Issue: 33
Author(s): Manfredi Rizzo, Alberto J.L. Macario, Everly Conway de Macario, Ioanna Gouni-Berthold, Heiner K. Berthold, Giovam Battista Rini, Giovanni Zummo and Francesco Cappello
Affiliation:
Keywords: Chaperonin, heat shock protein 60, cardiomyocytes, heart failure, cardiovascular disease, atherosclerosis, apoptosis, microRNAs (miRs), diabetes, Atrial fibrillation
Abstract: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecular chaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60, the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotective but a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examples of specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicate a pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response to treatment, as well as for preventing and treating CVD.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, J.L. Macario Alberto, Conway de Macario Everly, Gouni-Berthold Ioanna, K. Berthold Heiner, Battista Rini Giovam, Zummo Giovanni and Cappello Francesco, Heat Shock Protein-60 and Risk for Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220981
DOI https://dx.doi.org/10.2174/138161211798220981 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Features for Heartbeat Sound Signal Normal and Pathological
Recent Patents on Computer Science Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Recent Developments in the Field of Quinazoline Chemistry
Current Organic Chemistry The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mesoionic Oxatriazoles (MOTA): NO-Donating Characteristics and Pharmacology
Current Pharmaceutical Design Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?
Current Vascular Pharmacology Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation
Medicinal Chemistry Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Mini-Reviews in Medicinal Chemistry Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Can Erythrocyte Catalase Regulate Blood Pressure?
Cardiovascular & Hematological Agents in Medicinal Chemistry